The University of Milano (Unimi-www.unimi.it) is a public teaching and research university, a leading institution in Italy and Europe for scientific productivity. In this contest, the Department of Pharmacological and Biomolecular Sciences (DiSFeB) of Milan University was founded in 2012, and has been awarded by the Minister of Research as a Department of Excellence in the frame of a government project among Italian Universities, an extraordinary support of over 8 million euros devoted to strengthen and enhance the excellence of research and teaching, with investments in human capital, infrastructure and high qualification educational activities (2018-2022). In addition, the Centre of Excellence on Neurodegenerative Disease is located at DiSFeB and represents a multidisciplinary centre, which aims at studying the mechanisms involved in the onset and progression of neurodegenerative diseases and identifying prognosis markers as well as novel therapeutic strategies (http://www.cend.unimi.it/it/homepage/).

DiSFeB supports and coordinate basic research applied to biomedical and life sciences, linking together preclinical and clinical studies in order to discover new pharmacological targets and innovative therapy for human health. At the DiSFeB works together 250 persons, of which, 70 are professors and researchers permanently hired, there are up to 30 research groups with common interests and forefront technological and scientific platforms. Some DiSFeB laboratories are seconded to different centers of excellence (Institute/Hospital) in Milan area in order to generate a network of multidisciplinary skills and to link together preclinical and clinical studies. The DiSFeB promotes multidisciplinary research of drug sciences and related basic and applied sciences, combines scientific educational sectors, similar and complementary for technical-scientific expertise, to favor the development of cutting-edge research project and creates multidisciplinary scientific platforms to ensure a high-quality research. DiSFeB supports and coordinate basic research applied to biomedical and life sciences, including basic research in pharmacokinetics, pharmacology, immunology, cell biology, neuroscience, genomics, proteomics, and metabolomics. In addition, DiSFeB transfers technological and basic research findings and promotes a productive communication between public and private company interested in drug field and human health. The Borsello' laboratory is seconded to the IRCCS-IRFMN.

UNIMI will participate in WP1, WP2, WP8, and WP9